Key result
Riociguat inhibits platelet activation in whole blood only at concentrations above 50 μM, indicating that therapeutic plasma concentrations (150-500 nM) do not affect platelet function in patients.
Why the study?
Does riociguat inhibit platelet activation and aggregation in human platelets and whole blood?
Population
Human platelets and wild-type vs. platelet-specific sGC-knockout mice
Comparison
Riociguat alone or in combination with iloprost vs Control/untreated platelets; wild-type vs…
Design
Preclinical
Authors
Loading...
Supports no platelet inhibition at therapeutic riociguat levels; leaves open potential synergy with iloprost for further study.
Does riociguat inhibit platelet activation and aggregation in human platelets and whole blood?
Riociguat does not inhibit platelet function at therapeutic plasma concentrations in whole blood, though it may act synergistically with iloprost.
Mindukshev et al. (2015) studied this question. Riociguat was evaluated on Platelet activation and aggregation. Riociguat inhibits platelet activation in whole blood only at concentrations above 50 μM, indicating that therapeutic plasma concentrations (150-500 nM) do not affect platelet function in patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: